Skip to main content
TNXP
NASDAQ Life Sciences

Medicare Part D Win Adds 9M Lives to TONMYA Coverage as Tonix Bolsters Sales Force

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$13.06
Mkt Cap
$199.738M
52W Low
$10.03
52W High
$69.97
52W Position info
30% above low
Off High info
81% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

TNXP sits 30% above its 52-week low of $10.03.

Summary

Tonix Pharmaceuticals has secured a new Medicare Part D payer agreement for TONMYA, adding 9 million covered lives and pushing total expected coverage to 145 million lives by January 2027. The company is also expanding its sales force by 50 representatives.


Key Events · Product Development and Regulatory · TNXP

  • Medicare Part D Coverage Secured

    A new PBM agreement adds ~9M Medicare Part D lives, effective Jan 1, 2027, bringing total expected TONMYA coverage to ~145M lives (46% of U.S. covered lives).

  • Sales Force Expansion Underway

    By mid-Q3 2026, 50 new sales representatives will be deployed, increasing the total field force to approximately 150 to support TONMYA's commercial launch.

  • Commercial Access Milestone

    Combined with two prior GPO agreements and Medicaid in most states, this agreement significantly broadens patient access and revenue potential for the company's lead product.

  • Going-Concern Context

    The expanded coverage and sales force directly address the company's going-concern warning by accelerating TONMYA's commercial ramp and cash flow generation.


Analysis · TNXP · Life Sciences

A new pharmacy benefit manager agreement will extend TONMYA coverage to approximately 9 million Medicare Part D lives starting January 1, 2027. When combined with earlier commercial and Medicaid wins, total covered lives are projected to reach about 145 million—46% of all U.S. covered lives. To support the launch, the company is adding 50 sales representatives, bringing the field force to roughly 150 by mid-third quarter 2026. This milestone meaningfully expands commercial access for the flagship fibromyalgia drug and directly mitigates going-concern risk by accelerating the revenue trajectory.

How filings like this one have moved

In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNXP was trading at $13.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.7M. The 52-week trading range was $10.03 to $69.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNXP - Latest Insights

TNXP
Oct 27, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.36
Real-time Price: $5.19 info
Change: -$0.170 (-3%) info
Market Cap: $89.014M info
TNXP
Oct 15, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.42
Real-time Price: $5.19 info
Change: -$1.23 (-19%) info
Market Cap: $89.014M info
TNXP
Oct 02, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.93
Real-time Price: $5.19 info
Change: -$3.74 (-42%) info
Market Cap: $89.014M info
TNXP
Sep 22, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.78
Real-time Price: $5.19 info
Change: -$5.59 (-52%) info
Market Cap: $89.014M info
TNXP
Aug 10, 2026, 8:09 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.80
Real-time Price: $5.19 info
Change: -$6.61 (-56%) info
Market Cap: $89.014M info